^
Association details:
| Biomarker: | ADAM9 overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | izeltabart tapatansine (IMGC936) (Microtubule inhibitor, ADAM9-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1841 - IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models
Published date:
03/10/2021
Excerpt:
A majority of the tumor samples had medium to high levels of ADAM9 with 62% of non-small cell lung carcinoma (NSCLC), 65% of triple negative breast cancer (TNBC)...having H- scores of 101 to 300....Across the tumor types tested, IMGC936 was active or highly active in 24 out of 35 models (69%) with complete regressions in 6 models (4 NSCLC, 2 TNBC).
